We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Keryx Biopharmaceuticals, Inc. (delisted) | NASDAQ:KERX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.36 | 3.10 | 3.35 | 0 | 01:00:00 |
From May 2019 to May 2024
Cowen and Company 35th Annual Health Care Conference (Boston, MA) Presenter: Greg Madison, President and Chief Operating Officer Presentation Date: Monday, March 2nd, 2015 Presentation Time: 4:50 pm ET
27th Annual ROTH Conference (Dana Point, CA) Presenter: Abraham Ceesay, VP, Marketing and Operations Presentation Date: Monday, March 9th, 2015 Presentation Time: 9:00 am PT (12:00 noon ET)
Live audio webcasts of these presentations will be accessible within the Investor Relations section of the Company's Website at http://investors.keryx.com. An archived version of each webcast will be available following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, headquartered in New York, is focused on bringing innovative therapies to market for patients with renal disease. The Company launched its first FDA-approved product, Auryxia, in the United States in December 2014. In January 2014, ferric citrate was approved for the treatment of patients with all stages of CKD in Japan, where it is being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. For more information about Keryx, please visit www.keryx.com.
Hot Features
Premium
CONTACT: Amy Sullivan, Vice President - Corporate Development
and Public Affairs
Keryx Biopharmaceuticals, Inc.
Tel: 617.466.3447
E-mail: amy.sullivan@keryx.com
1 Year Keryx Biopharmaceuticals, Inc. (delisted) Chart |
1 Month Keryx Biopharmaceuticals, Inc. (delisted) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
